Efficacy and Safety of Tadalafil in Hemodialysis Patients

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to check the safety and efficacy of a pde5 inhibitor, tadalafil, is a special group of patients: Renal chronic patients in hemodialysis treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pernambuco
• Treatments: Tadalafil

Criteria

Inclusion Criteria:

• Men between 18 and 70 years old

• Diagnosticated ED for 6 months at least

• Accept the protocol

• Sign the informed consent

• Renal chronic patients in hemodyalisis

Exclusion Criteria:

• History of another PDE5 inhibittor use.

• C.C.I. grade III (NYHA)